Randomized, Double-blind, Placebo-controlled, Dose Escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin and/or Basal Insulin

Trial Profile

Randomized, Double-blind, Placebo-controlled, Dose Escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin and/or Basal Insulin

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Lixisenatide (Primary) ; Insulin; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 1 Aug 2018 to 27 Jul 2018.
    • 05 Jul 2017 Planned primary completion date changed from 1 Aug 2018 to 27 Jul 2018.
    • 01 Jun 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top